We’re excited to announce that the 23andMe Parkinson’s Research Community has exceeded its goal, enrolling more than 10,000 people with the disease and creating the largest cohort of genotyped people with Parkinson’s in the world.Reaching this milestone offers scientists an incredible opportunity to better understand the causes and potential treatments for this neurodegenerative disease. While we’ve already done important Parkinson’s research, it is what we hope to do in the future that is most exciting for researchers here at 23andMe.“Having reached this important milestone, the next step for us is to focus on the data that we have collected,” said 23andMe’s Parkinson’s Research Manager Emily Drabant, PhD. “This is a tremendously rich dataset and we want to learn as much as we can from it.”
23andMe started this initiative four years ago, as a way to accelerate research into Parkinson’s, and we’ve already shown how our model can do just that by quickly replicating known genetic associations with Parkinson’s and discovering previously unknown genetic associations with the disease.Now that we’ve reach this enrollment goal, we can delve into the data to better understand such things as:
• The relationship between environmental and genetic factors in the development of Parkinson’s.
• How those with Parkinson’s react differently to treatment so that treatments my be better individually targeted.
• And, by continuing to engage with our community members — who, through their courage in the face of this difficult illness, inspire us — we can better understand the disease and its progression.
We know that the possibilities for discovery continue to grow, and, with the continued partnership of our engaged Parkinson’s Research Community, we will move ever closer to a cure.